Form 4: ARS Pharmaceuticals Director Laura Shawver Executes Stock Options and Sells Shares
SEC Form 4 Filing
Director Laura Shawver exercised stock options and sold shares of ARS Pharmaceuticals, Inc. on February 3, 2025, according to a Form 4 filing with the SEC.
Summary
- On February 3, 2025, Laura Shawver, a director of ARS Pharmaceuticals, Inc. (SPRY), exercised stock options to acquire 9,064 shares at $3.15 and 40,936 shares at $4.85.
- Shawver then sold 50,000 shares of common stock at a weighted average price of $12.3113, with prices ranging from $11.9732 to $12.76.
- Following these transactions, Shawver directly owns 210,346 shares of ARS Pharmaceuticals.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 16, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity. The director is selling shares, which could be seen as slightly negative, but it's under a pre-arranged plan.
Industry Context
This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's perspective on the company's value.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/03/2025 | Date of stock option exercise and share sale |
| 02/04/2025 | Date of signature on the Form 4 filing |
| 05/01/2032 | Expiration date of some stock options |
| 01/31/2032 | Expiration date of some stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.